An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?

A medicine from AstraZeneca and Merck & Co. has become the first of its type to slow the return of a particularly aggressive, hereditary form of breast cancer, a significant finding that may push doctors to do more genetic testing in patients with the disease.